Cat designer declares war

The less-than-reputable entrepreneur at the helm of a company peddling hypo-allergenic cats is under scrutiny again -- this time for fraudulent "designer cats." But now he's taking the offensive by making allegations against journalists who have covered his company. In January of last year, The Scientist staff writer Kerry Grens investigated a company called Allerca that claimed to have created the world's first hypoallergenic cat. Grens uncovered a string of shady dealings and questionable

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share
The less-than-reputable entrepreneur at the helm of a company peddling hypo-allergenic cats is under scrutiny again -- this time for fraudulent "designer cats." But now he's taking the offensive by making allegations against journalists who have covered his company. In January of last year, The Scientist staff writer Kerry Grens investigated a company called Allerca that claimed to have created the world's first hypoallergenic cat. Grens uncovered a string of shady dealings and questionable science associated with the company, including the fact that its founder, Simon Brodie, had served two and a half years in jail for fraud. Read Grens' full story linkurl:here;http://www.the-scientist.com/2007/1/1/32/1/ and a follow-up story linkurl:here.;http://www.the-scientist.com/blog/display/54020/ Last month, San Diego Union-Tribune staff writer Penni Crabtree was investigating the Dutch seizure of three exotic cats that had been sold for about $40,000 by a U.S. company claiming to make designer cats. That company, known as LifeStyle Pets, happens to be an offshoot company of Allerca. The three seized cats were supposed to be a special mixed breed of "exotic" cats, called Ashera (you can read Crabtree's full story linkurl:here;http://www.signonsandiego.com/news/business/biotech/20080205-9999-1b5cats.html ). Over the course of Crabtree's reporting for the story, allegations emerged that the seized cats were not in fact a specially bred mix but just Savannah F1 cats, purchased from a breeder in Pennsylvania. On January 24, Crabtree called and Emailed Brodie for a response to the allegations. Instead of returning calls or Emails, the next day Brodie issued a press release that was picked up by Mass Media, a distribution newswire (read the release from Brodie's Web site linkurl:here;http://www.simonbrodie.com/NsPdf.PDF ). The press release accused Crabtree of accepting money from a competitive pet product company, Idexx Laboratories, in exchange for giving Cyntegra -- another of Brodie's pet companies -- bad press. According to the release, Crabtree is being investigated as part of a lawsuit that Cyntegra is pursuing against Idexx. The release also stated that Grens was being investigated for accepting money from Idexx. Idexx did not return two calls for comment. Crabtree told The Scientist that these accusations are ridiculous. Grens (now senior science reporter at WHYY in Philadelphia) wrote in an Email to The Scientist that she had never interacted with or spoke to anyone at Idexx, never accepted money from them, and was not aware that she was being investigated by Brodie. In response to the press release, Union-Tribune attorney Scott Wahrenbrock sent a letter to both Brodie and Mass Media demanding a retraction. Brodie did not respond, but privately sent out the press release again to hundreds of reporters, Wahrenbrock told The Scientist. He added that Mass Media linkurl:removed;http://www.mmdnewswire.com/despite-subpoen-2823.html Brodie's press release from their Web site and have assured Wahrenbrock that the retraction letter written by the Union-Tribune will be posted there within 24 hours. In a copy of the retraction letter Wahrenbrock sent to The Scientist, which you can read linkurl:here,;http://www.the-scientist.com/supplementary/pdf/54284/UnionTrib_Retract.pdf Wahrenbrock discounts most of the claims made by Brodie, in particular, that Crabtree accepted money to discredit a local businessman (Brodie), and that Crabtree is being investigated for taking money from a rival pet company. In response to a request for comment, Brodie wrote in an Email: "We will not be posting a retraction. I can only presume Mass Media is posting a retraction because they have been threatened by the [Union-Tribune's] attorneys (this is a fact), and not because they want to -- so much for free speech." He refused to provide any evidence against Grens, saying that it is in the hands of his investigators. He also refused to say who his investigators and attorneys are. "I don't know if anybody believes anything he says," Wahrenbrock said. But "he does bilk people out of money."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Andrea Gawrylewski

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

An illustration of different-shaped bacteria.

Leveraging PCR for Rapid Sterility Testing

Conceptual 3D image of DNA on a blue background.

Understanding the Nuts and Bolts of qPCR Assay Controls 

Bio-Rad